1 Jours


47. (Amended) A composition containing an anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.



- 49. (Amended) A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 with the exception that the asparagine codon at position 75 is replaced with a lysine.
- 54. (Amended) A composition comprising an anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.
- 55. (Amended) A composition comprising an anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.
- 56. (Amended) A composition comprising an anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.
- 57. (Amended) A composition comprising an anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.
- 58. (Amended) A composition comprising an anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.
- 59. (Amended) A composition comprising an anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.
- 60. (Amended) A composition comprising an anti-human CD23 antibody according to claim 54 and a pharmaceutically acceptable carrier. --

## Claims 61-70 are new claims:

- 61. The composition of claim 45, which composition is a pharmaceutical composition.



Attorney Reference: <u>037003-0275470</u>

- 62. The composition of claim 46, which composition is a pharmaceutical composition.
- 63. The composition of claim 47, which composition is a pharmaceutical composition.
- 64. The composition of claim 54, which composition is a pharmaceutical composition.
- 65. The composition of claim 55, which composition is a pharmaceutical composition.
- 66. The composition of claim 56, which composition is a pharmaceutical composition.
- 67. The composition of claim 57, which composition is a pharmaceutical composition.
- 68. The composition of claim 58, which composition is a pharmaceutical composition.
- 69. The composition of claim 59, which composition is a pharmaceutical composition.
- 70. The composition of claim 60, which composition is a pharmaceutical composition.

## **REMARKS**

This Reply is responsive to the Office Action dated October 22, 2002. Claims 45-47, 49, and 54-60 are amended, and new claims 61-70 are added. Entry of the foregoing amendments and reconsideration and reexamination of the application in light of the remarks that follow are respectfully requested.

